Novavax Inc (NAS:NVAX)
$ 9.44 0.32 (3.51%) Market Cap: 1.51 Bil Enterprise Value: 643.71 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 69/100

Novavax Inc at SVB Leerink Global Healthcare (Virtual) Transcript

Feb 16, 2022 / 04:20PM GMT
Release Date Price: $86.55 (-0.67%)
David Reed Risinger
SVB Leerink Holdings LLC - Senior MD

Great. So good morning, everyone, and thank you so much for joining the Novavax presentation and discussion at the SVB Healthcare Conference. My name is Dave Risinger, and I cover diversified biopharmaceuticals. And it's my pleasure to welcome John Trizzino and Filip Dubovsky. I'm going to give them a very brief introduction and then pass it to Filip to go through some slides.

So John Trizzino is Executive Vice President, Chief Business Officer and Chief Commercial Officer, with responsibility for global commercial strategy and execution and oversight of IT, investor public relations and corporate affairs. He has extensive experience in publicly held companies and in vaccines. Since rejoining Novavax in 2014, he's held roles of increasing responsibility, including Chief Financial Officer and Senior Vice President of Commercial Operations. Filip Dubovsky is Executive Vice President, Chief Medical Officer, with responsibility for medical and clinical affairs and related activities at Novavax. A recognized leader in vaccine development, Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot